*The following content is generated by AI and is for reference only.
Favipiravir, chemically known as 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, is a novel antiviral drug with the molecular formula C5H4FN3O2 and CAS Registry Number 1019578-69-6. Originally developed by Toyama Chemical, a subsidiary of Fujifilm, this compound was initially investigated for its potential efficacy against influenza viruses but has since expanded its scope to include other RNA viruses such as Ebola, Marburg, and various emerging coronaviruses including SARS-CoV-2. Its mechanism of action involves inhibition of viral RNA-dependent RNA polymerase (RdRp). Unlike many existing nucleoside analogues, Favipiravir acts as a guanosine mimic that gets incorporated into the growing viral RNA chain, causing lethal mutagenesis and ultimately halting viral replication. This unique mode of action makes it particularly valuable against viruses that have developed resistance to neuraminidase inhibitors or other standard treatments.
Approved for medical use in Japan in 2014 for severe influenza cases where standard therapies fail, Favipiravir gained global attention during the recent pandemic due to its broad-spectrum activity. Clinical trials across multiple countries have evaluated its effectiveness in treating mild to moderate COVID-19 patients, showing promising results in reducing viral load and shortening recovery time. The drug is typically administered orally in tablet form, offering a convenient route for outpatient management. While generally well-tolerated, common side effects may include elevated uric acid levels, diarrhea, and nausea. It is contraindicated in pregnant women due to teratogenic risks observed in animal studies. As research continues, Favipiravir remains a critical candidate in the global arsenal against future viral outbreaks, highlighting its versatility as a frontline therapeutic agent for acute respiratory infections caused by diverse RNA pathogens.